Emerging Markets, Acquisitions Prop Up Growth At Sanofi Aventis
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Viehbacher signals more acquisitions and radical changes in R&D as generics begin to bite into key brands including Plavix.
You may also be interested in...
Sanofi Beats GSK To Buy Merieux Alliance's Stake In India's Shantha Biotech; Move Aimed At Stronger Vaccines Business In Emerging Markets
Shantha's pipeline includes Rotavirus, conjugated typhoid and HPV vaccines.
GSK’s Viehbacher To Head Sanofi-Aventis
Sanofi-Aventis gains a new leader with the departure of North American Pharma Head Viehbacher from GlaxoSmithKline.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.